We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
If the vaccine is approved, the shot is expected to be shipped worldwide via the World Health Organization-backed COVAX vaccine-sharing program. Read More
Astellas Pharma has stopped enrolling and dosing in a phase 1/2 clinical trial of its genetic therapy AT132 for X-linked myotubular myopathy, a rare neuromuscular disease, after a subject suffered a serious adverse event. Read More
Johnson & Johnson’s (J&J) vaccine technology that has been successful in its COVID-19 vaccine has not worked against human immunodeficiency virus (HIV), a more complex virus. Read More
CAR-T therapies make use of T-cells harvested from volunteers, which are then genetically altered to recognize cancer cells and inserted into patients to attack their tumors. Read More
Gantenerumab, Roche’s prime contender of Alzheimer disease drugs in the antiamyloid antibody space, has been around the block a few times in a series of failed phase 3 studies with the suffix “RoAD.” Read More
Novartis said its chimeric antigen receptor T-cell (CAR-T) therapy Kymriah (tisagenlecleucel) failed to boost survival in patients with aggressive B-cell nonHodgkin lymphoma in a phase 3 study. Read More
The FDA’s recent approval of Biogen’s Alzheimer’s disease treatment Aduhelm has encouraged a new roster of contenders, including Eli Lilly’s Donanemab, a relative newcomer to the antiamyloid antibody space. Read More
The global late-stage trial contained 25 cases of symptomatic COVID-19 at the time of the primary analysis, with the study enrolling almost 5,200 total participants. Read More